BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27309985)

  • 21. Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An
    Usmani OS; Mignot B; Kendall I; Maria R; Cocconi D; Georges G; Scichilone N
    J Aerosol Med Pulm Drug Deliv; 2021 Jun; 34(3):204-211. PubMed ID: 33052749
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers.
    Luo Z; Lucci G; Santoro L; Topole E; Mariotti F
    Pulm Pharmacol Ther; 2022 Jun; 73-74():102129. PubMed ID: 35525480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
    Solidoro P; Patrucco F; Bagnasco D
    Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
    [No Abstract]   [Full Text] [Related]  

  • 24. Beclometasone for chronic obstructive pulmonary disease.
    De Coster DA; Jones M; Thakrar N
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009769. PubMed ID: 24105424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses.
    Papi A; Virchow JC; Singh D; Kots M; Vele A; Georges G; Canonica GW
    J Allergy Clin Immunol; 2021 Jul; 148(1):262-265.e2. PubMed ID: 33485959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ethnic Sensitivity Study of the Extrafine, Single-Inhaler, Triple Therapy Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide Pressurized Metered Dose Inhaler in Japanese and Caucasian Healthy Individuals: A Randomized, Double-Blind, Single-Dose Crossover Study.
    Cella M; Täubel J; Delestre-Levai I; Tulard A; Vele A; Georges G
    Clin Ther; 2021 Nov; 43(11):1934-1947.e4. PubMed ID: 34600734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids.
    Paggiaro P; Corradi M; Latorre M; Raptis H; Muraro A; Gessner C; Siergiejko Z; Scuri M; Petruzzelli S
    BMC Pulm Med; 2016 Dec; 16(1):180. PubMed ID: 27938358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England.
    Orlovic M; Magni T; Lukyanov V; Guerra I; Madoni A
    Respir Med; 2022 Sep; 201():106934. PubMed ID: 35872377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD.
    Ming SWY; Haughney J; Ryan D; Small I; Lavorini F; Papi A; Singh D; Halpin DMG; Hurst JR; Patel S; Ochel M; Kocks J; Carter V; Hardjojo A; Price DB
    Int J Chron Obstruct Pulmon Dis; 2020; 15():3093-3103. PubMed ID: 33273812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease (COPD) in an Italian Context of Real Life: The TRITRIAL Study Protocol.
    Richeldi L; Piraino A; Macagno F; Micarelli G; Ingrassia E
    Int J Chron Obstruct Pulmon Dis; 2021; 16():159-166. PubMed ID: 33536751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD.
    Singh D; Nicolini G; Bindi E; Corradi M; Guastalla D; Kampschulte J; Pierzchała W; Sayiner A; Szilasi M; Terzano C; Vestbo J;
    BMC Pulm Med; 2014 Mar; 14():43. PubMed ID: 24621109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease.
    Kupczyk M; Kuna P
    Expert Rev Respir Med; 2019 Jan; 13(1):5-11. PubMed ID: 30463457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution.
    Braido F; Corsico AG; Paleari D; Piraino A; Cavalieri L; Scichilone N
    Ther Adv Respir Dis; 2022; 16():17534666211066063. PubMed ID: 35044875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
    Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
    Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolving to a single inhaler extrafine LABA/LAMA/ICS - Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE).
    Brusselle G; Himpe U; Fievez P; Leys M; Perez Bogerd S; Peché R; Vanderhelst E; Lins M; Capiau P;
    Respir Med; 2023 Nov; 218():107368. PubMed ID: 37562659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma.
    Corradi M; Spinola M; Petruzzelli S; Kuna P
    Ther Adv Respir Dis; 2016 Oct; 10(5):492-502. PubMed ID: 27340255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of extrafine formulation of BDP/FF inhaler on asthma control, small airway function and airway inflammation among Mexican asthmatic patients. A retrospective analysis.
    Díaz-García R; Flores-Ramírez G; Ramírez-Oseguera RT
    Respir Med; 2020; 165():105932. PubMed ID: 32308205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
    Singh D; Virchow JC; Canonica GW; Vele A; Kots M; Georges G; Papi A
    Respir Res; 2020 Oct; 21(1):285. PubMed ID: 33121501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.
    Calzetta L; Matera MG; Facciolo F; Cazzola M; Rogliani P
    Respir Res; 2018 Apr; 19(1):65. PubMed ID: 29650006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.